IN THE SPOTLIGHT

Amivantamab Plus Lazertinib Yields OS Advantage in Asia Cohort of MARIPOSA Trial in EGFR-Mutated NSCLC

Amivantamab Plus Lazertinib Yields OS Advantage in Asia Cohort of MARIPOSA Trial in EGFR-Mutated NSCLC

New Subcutaneous Amivantamab Combo Dosing Schedule Shows Promising Safety and Efficacy in EGFR-Positive NSCLC

New Subcutaneous Amivantamab Combo Dosing Schedule Shows Promising Safety and Efficacy in EGFR-Positive NSCLC

LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer

LncRNA EUDAL shapes tumor cell response to hypoxia-induced constitutive EGFR activation and promotes chemoresistance in oral cancer

SC Amivantamab Consistent with IV Formulation in EGFR-Mutated NSCLC

SC Amivantamab Consistent with IV Formulation in EGFR-Mutated NSCLC

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC

Point-of-care creatinine-based eGFR (StatSensor) in detecting kidney dysfunction (KD) among people living with HIV in Tanzania

Point-of-care creatinine-based eGFR (StatSensor) in detecting kidney dysfunction (KD) among people living with HIV in Tanzania

What Patients With Lung Cancer Need to Know About EGFR PACC Mutations

What Patients With Lung Cancer Need to Know About EGFR PACC Mutations

Positive Buy Rating for Cullinan Management Driven by Promising Zipalertinib Trial Results in NSCLC with Uncommon EGFR Mutations

Positive Buy Rating for Cullinan Management Driven by Promising Zipalertinib Trial Results in NSCLC with Uncommon EGFR Mutations

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer

Subcutaneous amivantamab plus lazertinib yields high response in EGFR-mutant lung cancer